Maximus, Inc. (MMS) Lifted to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of Maximus, Inc. (NYSE:MMS) from a sell rating to a hold rating in a research note released on Wednesday.
According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “
Other equities analysts also recently issued research reports about the company. BidaskClub downgraded Maximus from a hold rating to a sell rating in a report on Monday, July 24th. Canaccord Genuity downgraded Maximus from a buy rating to a hold rating and set a $62.00 price objective on the stock. in a report on Tuesday, July 4th. Jefferies Group LLC downgraded Maximus from a buy rating to a hold rating and increased their price objective for the stock from $63.00 to $64.00 in a report on Friday, May 5th. ValuEngine downgraded Maximus from a buy rating to a hold rating in a report on Tuesday, May 16th. Finally, Maxim Group downgraded Maximus from a buy rating to a hold rating and set a $66.00 price objective on the stock. in a report on Thursday, May 4th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. Maximus currently has an average rating of Hold and a consensus price target of $61.00.
Maximus (NYSE MMS) opened at 60.41 on Wednesday. Maximus has a 12 month low of $43.69 and a 12 month high of $64.97. The firm has a market capitalization of $3.92 billion, a PE ratio of 19.81 and a beta of 1.40. The firm’s 50-day moving average is $62.10 and its 200-day moving average is $60.64.
Maximus (NYSE:MMS) last released its quarterly earnings data on Thursday, May 4th. The health services provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Maximus had a return on equity of 26.21% and a net margin of 8.18%. The firm had revenue of $622 million for the quarter, compared to the consensus estimate of $620.24 million. During the same quarter in the prior year, the company posted $0.74 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. On average, equities research analysts expect that Maximus will post $3.05 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.045 per share. The ex-dividend date is Friday, August 11th. This represents a $0.18 dividend on an annualized basis and a yield of 0.30%. Maximus’s payout ratio is currently 5.86%.
In other Maximus news, Director Paul R. Lederer sold 8,210 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $61.83, for a total transaction of $507,624.30. Following the completion of the sale, the director now owns 51,984 shares of the company’s stock, valued at $3,214,170.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel David Francis sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $60.46, for a total value of $60,460.00. Following the sale, the general counsel now directly owns 15,715 shares of the company’s stock, valued at approximately $950,128.90. The disclosure for this sale can be found here. Insiders have sold 109,846 shares of company stock valued at $6,893,986 in the last ninety days. Company insiders own 3.10% of the company’s stock.
Large investors have recently made changes to their positions in the company. Two Sigma Investments LP bought a new stake in shares of Maximus during the fourth quarter worth about $258,000. American International Group Inc. boosted its stake in shares of Maximus by 4.1% in the first quarter. American International Group Inc. now owns 166,652 shares of the health services provider’s stock worth $10,366,000 after buying an additional 6,634 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Maximus by 2.5% in the first quarter. Louisiana State Employees Retirement System now owns 16,400 shares of the health services provider’s stock worth $1,020,000 after buying an additional 400 shares during the last quarter. Navellier & Associates Inc boosted its stake in shares of Maximus by 10.9% in the first quarter. Navellier & Associates Inc now owns 8,737 shares of the health services provider’s stock worth $543,000 after buying an additional 856 shares during the last quarter. Finally, Advantus Capital Management Inc boosted its stake in shares of Maximus by 3.1% in the first quarter. Advantus Capital Management Inc now owns 8,298 shares of the health services provider’s stock worth $516,000 after buying an additional 248 shares during the last quarter. 97.89% of the stock is owned by hedge funds and other institutional investors.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.